NY 865151: The tariff classification of 5-amino-4-imidazole carboxamideribonucleotide from Japan

Native CBP ruling rendition. Applicability is fact-specific; modification/revocation relationships and original publisher date are retained. Publisher sentinel year0001 means unknown date, not a historical legal adoption.

                          
                                   NY 865151

                               August 15, 1991


CLA-2-29:S:N:N1:238 865151  

CATEGORY:  Classification

TARIFF NO.: 2934.90.4700  

Mr. Lawrence D. Blume
Graham & James
2000 M Street, N.W., Suite 700
Washington, DC 20036-3113

RE:  The tariff classification of 5-amino-4-imidazole carboxamide
ribonucleotide from Japan

Dear Mr. Blume:

     In your letter dated July 9, 1991, on behalf of Kyowa Hakko
USA, Inc., you requested a tariff classification ruling.

     The product 5-amino-4-imidazole carboxamide ribonucleotide,
having the CAS # 3031-94-5 is also known as "AICAR", 5-amino-4-
imidazole carboxamide ribonucleotide and 5-amino-1-(5-o-
phosphono-beta-D-ribofuranosyl)-1H-imidazol-4-carboxamide.  It
will be imported in bulk form for use as the active ingredient in
a cardiovascular drug.
     
     The applicable subheading for the 5-amino-4-imidazole
carboxamide ribonucleotide will be 2934.90.4700, Harmonized
Tariff Schedule of the United States (HTS), which provides for 
other heterocyclic compounds, other, other, drugs.  The rate of
duty will be 3.7 percent ad valorem.   

     This merchandise may be subject to the regulations of the
Food and Drug Administration.  You may contact them at 5600
Fishers Lane, Rockville, Maryland 20857, telephone number (202)
443-3380.

     This ruling is being issued under the provisions of Section
177 of the Customs Regulations (19 C.F.R. 177).

     A copy of this ruling letter should be attached to the entry
documents filed at the time this merchandise is imported.  If the
documents have been filed without a copy, this ruling should be
brought to the attention of the Customs officer handling the
transaction.



                                   Sincerely,

                                   
  
                                   Jean F. Maguire
                                   Area Director
                                   New York Seaport